Physician profile
Alan Gruber
NPI 1356345839
$1,046.78
in general payments reported to CMS, 2019-2025
14 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $190 · 2021: $112 · 2023: $96.98 · 2024: $174 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $466.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $466.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $258.84 | 2023-2025 | Rocklatan, Tryptyr, Clareon |
| Allergan, INC. | $173.80 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $138.60 | 2019 | |
| Glaukos Corporation | $112.41 | 2021 | |
| Sight Sciences, INC. | $99.07 | 2020 | |
| Biotissue Holdings INC. | $56.72 | 2023-2025 | |
| Oyster Point Pharma, INC. | $54.36 | 2024-2025 | Tyrvaya, Ryzumvi |
| Johnson & Johnson Surgical Vision, INC. | $35.70 | 2019-2024 | Tecnis Simplicity |
| Bausch & Lomb Americas INC. | $31.72 | 2023-2025 | Envista Mx60 Iol, Miebo |
| Thea Pharma INC. | $24.00 | 2024 | Iyuzeh |
| Ivantis, INC | $23.02 | 2020 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Harrow Eye, LLC | $19.14 | 2025 | Vevye |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Gruber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.